Chemotherapy treats leukemia by killing cancer cells that are dividing rapidly in your bone marrow and bloodstream. It does this by damaging the DNA inside those cells or blocking the chemical processes they need to copy themselves, which forces them into a programmed death sequence. Because leukemia cells multiply faster than most normal cells, they’re especially vulnerable to these drugs. The trade-off is that some healthy fast-dividing cells, like those in your gut lining and hair follicles, get caught in the crossfire, which is what causes many of chemo’s well-known side effects.
How Chemo Damages Leukemia Cells
Chemotherapy drugs attack leukemia cells through several different mechanisms, and doctors often combine drugs that work in different ways to make treatment more effective. The common thread is that all of them interfere with how a cell copies its DNA or holds itself together during division.
Some drugs block the enzymes that unwind DNA strands so they can be copied. When these enzymes are disabled, the DNA breaks apart permanently, and the cell can’t repair the damage. Other drugs starve cells of the raw materials they need to build new DNA. By cutting off the supply of these molecular building blocks, the cell stalls mid-replication and dies. A third category works by physically bonding to both strands of the DNA double helix, essentially gluing them together so they can’t separate. This halts both replication and the cell’s ability to read its own genetic instructions, triggering death.
These aren’t gentle processes. The drugs cause irreversible breaks in the cell’s genetic material, scrambling chromosomes and forcing the cell into apoptosis, the body’s built-in self-destruct program. The goal is to overwhelm the leukemia cells’ ability to repair themselves faster than the damage accumulates.
Treatment Phases for Acute Leukemia
Acute leukemias (both the lymphoblastic and myeloid types) grow fast and need aggressive treatment. Chemotherapy is typically structured in distinct phases, each with a specific goal.
The first phase is called induction. Its purpose is straightforward: kill enough leukemia cells in the blood and bone marrow to achieve remission. For acute myeloid leukemia (AML), the standard induction regimen has been used for nearly five decades. It pairs two drugs, one given for seven consecutive days and another for three days, which is why oncologists call it the “7+3” regimen. Remission is defined precisely: fewer than 5% immature cancer cells (blasts) remaining in the bone marrow, with white blood cells and platelets recovering to functional levels.
The second phase is consolidation, sometimes called remission continuation therapy. Even after induction puts the leukemia into remission, residual cancer cells can hide in the marrow at levels too low to detect on a standard test. Consolidation therapy targets those survivors to prevent relapse. For acute lymphoblastic leukemia (ALL), some treatment plans also include a longer maintenance phase with lower-dose drugs taken over months or years.
Protection for the Brain and Spinal Cord
Leukemia cells can cross into the fluid surrounding the brain and spinal cord, where most standard chemotherapy drugs can’t reach them in high enough concentrations. To prevent this, doctors deliver chemotherapy directly into the spinal fluid through a lumbar puncture. This is called intrathecal chemotherapy, and it’s given during multiple phases of treatment. The three most commonly used drugs for this are methotrexate, cytarabine, and corticosteroids. This step is especially important in ALL, where the risk of central nervous system involvement is higher.
How Chronic Leukemia Treatment Differs
Chronic leukemias, including chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML), behave differently from acute forms. They grow more slowly, and treatment doesn’t always need to start right away. Some people with early-stage CLL are monitored for years before they need any treatment at all.
When treatment does begin, traditional chemotherapy plays a smaller role than it used to. CML was transformed by the development of targeted drugs that block the specific protein driving the cancer’s growth. These are taken as daily pills and can keep the disease controlled for decades in many patients. For CLL, treatment has increasingly shifted toward targeted therapies that interrupt the signals leukemia cells use to survive and multiply, often combined with antibody-based drugs that flag cancer cells for destruction by the immune system. Traditional chemotherapy drugs like fludarabine and cyclophosphamide are still used in some CLL regimens, but they’re no longer the default first choice for most patients.
What Happens to Your Blood Counts
Intensive chemotherapy doesn’t distinguish perfectly between leukemia cells and the healthy stem cells in your bone marrow that produce normal blood cells. During induction, your blood counts drop dramatically before they recover. This period, called the nadir, is the most dangerous stretch of treatment.
In ALL induction, white blood cells typically bottom out around day 17, dropping to levels so low that the immune system is essentially nonfunctional. Platelets, which control bleeding, tend to hit their lowest point around day 10. Partial platelet recovery usually begins around day 18, with full recovery closer to day 25. During this window, you’re at high risk for infections and bleeding, which is why induction chemotherapy requires hospitalization, often for several weeks.
Chemotherapy is delivered through a central venous line rather than a regular IV in the arm. These lines, placed in a large vein in the chest or threaded through the upper arm, provide reliable access that can handle the concentrated drugs without damaging smaller veins. They also spare you from repeated needle sticks during a treatment course that involves frequent blood draws and multiple drug infusions.
Tumor Lysis Syndrome
When chemotherapy kills a large number of leukemia cells at once, those dying cells dump their internal contents into the bloodstream. This flood of potassium, phosphorus, and nucleic acids can overwhelm the kidneys and throw off the body’s electrolyte balance, a condition called tumor lysis syndrome. It’s most common in leukemias with very high white blood cell counts at diagnosis, where the sheer volume of cancer cells means more cellular debris when treatment starts.
Doctors anticipate this by hydrating you aggressively before chemo begins and giving medications that help the body process uric acid, one of the breakdown products that can crystallize in the kidneys. For patients at the highest risk, a more powerful drug can be given intravenously to break down uric acid directly. Lab work is monitored closely in the first 48 to 72 hours of treatment to catch any dangerous shifts early.
How Effective Chemotherapy Is
Effectiveness varies enormously depending on the type of leukemia, the patient’s age, and the specific genetic mutations driving the cancer. For AML, the five-year relative survival rate is about 33%, based on data from 2015 through 2021. That number reflects all ages, and outcomes are significantly better for younger patients. Children and younger adults with AML have considerably higher cure rates, while outcomes for patients over 60 are more challenging because they’re less able to tolerate intensive chemotherapy.
ALL has better overall survival rates, particularly in children, where cure rates with chemotherapy-based regimens exceed 85% in many studies. Adults with ALL have lower but improving survival rates as newer targeted drugs and immunotherapies are added to traditional chemo backbones. For chronic leukemias, the picture is different entirely. Many patients with CML now have near-normal life expectancy on targeted therapy, and CLL patients on modern regimens can achieve years of disease control, with chemotherapy playing a supporting rather than central role.